Cargando…
Bioinformatical Design and Performance Evaluation of a Nucleocapsid- and an RBD-Based Particle Enhanced Turbidimetric Immunoassay (PETIA) to Quantify the Wild Type and Variants of Concern-Derived Immunoreactivity of SARS-CoV-2
Since SARS-CoV-2 emerged in December 2019 in Wuhan, the resulting pandemic has paralyzed the economic and cultural life of the world. Variants of concern (VOC) strongly increase pressure on public health systems. Rapid, easy-to-use, and cost-effective assays are essential to manage the pandemic. Her...
Autores principales: | Wey, Leoni, Masetto, Thomas, Spaeth, Alexander, Brehm, Jessica, Kochem, Christian, Reinhart, Marco, Müller, Holger, Kempin, Uwe, Lorenz, Franziska, Peter, Christoph, Grimmler, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855841/ https://www.ncbi.nlm.nih.gov/pubmed/36672668 http://dx.doi.org/10.3390/biomedicines11010160 |
Ejemplares similares
-
Characterization of the Diagnostic Performance of a Novel COVID-19 PETIA in Comparison to Four Routine N-, S- and RBD-Antigen Based Immunoassays
por: Spaeth, Alexander, et al.
Publicado: (2021) -
Analytical validation of Gentian NGAL particle-enhanced enhanced turbidimetric immunoassay (PETIA)
por: Salvagno, Gian Luca, et al.
Publicado: (2017) -
SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients – a comparative long term post-infection study
por: Brehm, Jessica, et al.
Publicado: (2022) -
A new turbidimetric immunoassay for serum calprotectin for fully automatized clinical analysers
por: Nilsen, Tom, et al.
Publicado: (2015) -
Quantification of human C1 esterase inhibitor protein using an automated turbidimetric immunoassay
por: Tange, Clare E., et al.
Publicado: (2018)